Inhibikase Therapeutics (IKT) Cash from Investing Activities (2022 - 2026)

Inhibikase Therapeutics (IKT) has 5 years of Cash from Investing Activities data on file, last reported at -$80.5 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 482.27% year-over-year to -$80.5 million in Q1 2026; TTM through Mar 2026 was -$99.5 million, a 687.19% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, up 105.55% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$80.5 million, down from -$98847.0 in the prior quarter.
• Over the last five years, Cash from Investing Activities for IKT reached as high as $21.1 million in Q1 2025 and fell as low as -$80.5 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$7.5 million across 5 years, with a median of -$70968.0 in 2022.
• Across the five-year window, Cash from Investing Activities surged 6017.7% in 2023 and plunged 1732.19% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $5.0 million in 2022, then plunged by 142.63% to -$2.1 million in 2023, then plunged by 1732.19% to -$38.8 million in 2024, then jumped by 99.74% to -$98847.0 in 2025, then slumped by 81323.4% to -$80.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$80.5 million in Q1 2026, -$98847.0 in Q4 2025, and -$28.7 million in Q3 2025.